Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 726

1.

Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD.

Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2019 Nov 5;4(1):66-76. doi: 10.1002/hep4.1445. eCollection 2020 Jan.

2.

Establishment of a New Three-Dimensional Dose Evaluation Method Considering Variable Relative Biological Effectiveness and Dose Fractionation in Proton Therapy Combined with High-Dose-Rate Brachytherapy.

Kobayashi D, Isobe T, Takada K, Mori Y, Takei H, Kumada H, Kamizawa S, Tomita T, Sato E, Yokota H, Sakae T.

J Med Phys. 2019 Oct-Dec;44(4):270-275. doi: 10.4103/jmp.JMP_117_18. Epub 2019 Dec 11.

3.

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.

Kawaguchi I, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, Kumada H.

Adv Ther. 2020 Jan;37(1):457-476. doi: 10.1007/s12325-019-01166-3. Epub 2019 Dec 5.

PMID:
31808054
4.

Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.

Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Nov 30. doi: 10.1111/hepr.13467. [Epub ahead of print]

PMID:
31785120
5.

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.

Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H.

J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12.

6.

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver.

Ogasawara N, Saitoh S, Denpou H, Kinowaki K, Akuta N, Suzuki F, Hashimoto M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Fujii T, Kumada H.

Intern Med. 2019 Oct 17. doi: 10.2169/internalmedicine.3577-19. [Epub ahead of print]

7.

3D-printable lung phantom for distal falloff verification of proton Bragg peak.

Koketsu J, Kumada H, Takada K, Takei H, Mori Y, Kamizawa S, Hu Y, Sakurai H, Sakae T.

J Appl Clin Med Phys. 2019 Sep;20(9):86-94. doi: 10.1002/acm2.12706.

8.

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease.

Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Intern Med. 2019 Sep 18. doi: 10.2169/internalmedicine.3555-19. [Epub ahead of print]

9.

Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.

Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK.

J Clin Pharmacol. 2019 Sep 12. doi: 10.1002/jcph.1524. [Epub ahead of print]

PMID:
31515816
10.

Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.

Ogasawara N, Saitoh S, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Dec;49(12):1441-1450. doi: 10.1111/hepr.13418. Epub 2019 Oct 9.

PMID:
31373093
11.

Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.

Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H.

Hepatol Res. 2019 Dec;49(12):1406-1413. doi: 10.1111/hepr.13415. Epub 2019 Aug 9.

PMID:
31347756
12.

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.

Sano T, Akuta N, Suzuki F, Kasuya K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2019 Sep 15;58(18):2657-2662. doi: 10.2169/internalmedicine.2604-18. Epub 2019 Jun 7.

13.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.

Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Gastroenterol. 2019 Oct;54(10):916-927. doi: 10.1007/s00535-019-01575-9. Epub 2019 Mar 22.

PMID:
30903385
14.

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.

Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E, Bhagat A, Mensa FJ, Otani T, Larsen L, Burroughs M, Kumada H.

J Gastroenterol. 2019 Aug;54(8):752-761. doi: 10.1007/s00535-019-01569-7. Epub 2019 Mar 13.

15.

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H.

J Gastroenterol. 2019 Aug;54(8):742-751. doi: 10.1007/s00535-019-01568-8. Epub 2019 Mar 8.

PMID:
30848363
16.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies.

Suzuki H, Kawamura Y, Kinowaki K, Akuta N, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2019 Jul 1;58(13):1891-1895. doi: 10.2169/internalmedicine.2374-18. Epub 2019 Feb 25.

17.

Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection.

Wei L, Kumada H, Perumalswami PV, Tanwandee T, Cheng W, Heo J, Cheng PN, Hwang P, Mu SM, Zhao XM, Asante-Appiah E, Caro L, Hanna GJ, Robertson MN, Haber BA, Talwani R.

J Gastroenterol Hepatol. 2019 Sep;34(9):1597-1603. doi: 10.1111/jgh.14636. Epub 2019 Apr 17.

PMID:
30779220
18.

Synthesis of the Non Reducing End Oligosaccharides of Glycosphingolipids from Ascaris suum.

Hada N, Umeda Y, Kumada H, Shimazaki Y, Yamano K, Schweizer F, Oshima N, Takeda T, Kiuchi F.

Chem Pharm Bull (Tokyo). 2019;67(2):143-154. doi: 10.1248/cpb.c18-00768.

19.

Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.

Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Aliment Pharmacol Ther. 2019 Feb;49(4):457-471. doi: 10.1111/apt.15108. Epub 2019 Jan 20. Erratum in: Aliment Pharmacol Ther. 2019 Jul;50(2):234-235.

PMID:
30663078
20.

Biomolecule-Assisted Synthesis of Hierarchical Multilayered Boehmite and Alumina Nanosheets for Enhanced Molybdenum Adsorption.

Saptiama I, Kaneti YV, Yuliarto B, Kumada H, Tsuchiya K, Fujita Y, Malgras V, Fukumitsu N, Sakae T, Hatano K, Ariga K, Sugahara Y, Yamauchi Y.

Chemistry. 2019 Mar 27;25(18):4843-4855. doi: 10.1002/chem.201900177. Epub 2019 Mar 5.

PMID:
30652362
21.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.

Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 May;49(5):531-539. doi: 10.1111/hepr.13304. Epub 2019 Feb 6.

PMID:
30577089
22.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases.

Ohya K, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kinowaki K, Fujii T, Kondo F, Kumada H.

Hepatol Res. 2019 Jun;49(6):711-717. doi: 10.1111/hepr.13295. Epub 2019 Jan 8.

PMID:
30537443
23.

DEPTH DISTRIBUTIONS OF RBE-WEIGHTED DOSE and PHOTON-ISOEFFECTIVE DOSE FOR BORON NEUTRON CAPTURE THERAPY.

Sato T, Masunaga SI, Kumada H, Hamada N.

Radiat Prot Dosimetry. 2019 May 1;183(1-2):247-250. doi: 10.1093/rpd/ncy235.

PMID:
30535354
24.

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study.

Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Liver Cancer. 2018 Oct;7(4):323-334. doi: 10.1159/000487311. Epub 2018 Mar 14.

25.

Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.

Okada M, Hai H, Tamori A, Uchida-Kobayashi S, Enomoto M, Kumada H, Kawada N.

Clin J Gastroenterol. 2019 Jun;12(3):213-217. doi: 10.1007/s12328-018-0922-9. Epub 2018 Nov 16.

PMID:
30446954
26.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.

Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

BMC Gastroenterol. 2018 Nov 6;18(1):165. doi: 10.1186/s12876-018-0900-1.

27.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.

Akuta N, Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01463-18. doi: 10.1128/JCM.01463-18. Print 2019 Jan.

28.

No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.

Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H.

Hepatol Res. 2019 Feb;49(2):164-176. doi: 10.1111/hepr.13254. Epub 2018 Nov 6.

PMID:
30277295
29.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.

Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.

J Gastroenterol. 2019 Feb;54(2):182-193. doi: 10.1007/s00535-018-1502-y. Epub 2018 Aug 22.

PMID:
30136216
30.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Takeuchi Y, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Mar;49(3):256-263. doi: 10.1111/hepr.13242. Epub 2018 Sep 23.

PMID:
30125438
31.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2019 Jan;91(1):102-106. doi: 10.1002/jmv.25278. Epub 2018 Sep 3.

PMID:
30091810
32.

Cross-over study in hyperammonemia patients for efficacy, safety, and acceptability of a new lactulose preparation (SK-1202) compared to approved drug.

Yoshiji H, Karino Y, Suzuki Y, Suzuki F, Uejima M, Aikata H, Chayama K, Iwai H, Suzuki E, Kumada H.

Hepatol Res. 2018 Dec;48(13):1178-1183. doi: 10.1111/hepr.13228. Epub 2018 Aug 9.

PMID:
30005445
33.

Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study.

Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, Akuta N, Ito K, Kawanaka M, Hiramatsu A, Sakamoto M, Harada K, Goto Y, Nakayama T, Kumada H, Okanoue T.

Hepatol Res. 2018 Dec;48(13):1099-1107. doi: 10.1111/hepr.13226. Epub 2018 Aug 6.

PMID:
29974624
34.

Investigation of the neutron spectrum measurement method for dose evaluation in boron neutron capture therapy.

Onishi T, Kumada H, Takada K, Naito F, Kurihara T, Sakae T.

Appl Radiat Isot. 2018 Oct;140:5-11. doi: 10.1016/j.apradiso.2018.06.004. Epub 2018 Jun 11.

PMID:
29936276
35.

Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance.

Akuta N, Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Oct;90(10):1586-1592. doi: 10.1002/jmv.25238. Epub 2018 Jul 10.

PMID:
29896794
36.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis.

Kuwano T, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2018 Sep 1;57(17):2511-2515. doi: 10.2169/internalmedicine.0585-17. Epub 2018 Mar 30.

37.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Sep;48(10):810-813. doi: 10.1111/hepr.13075. Epub 2018 Apr 24.

PMID:
29601141
38.

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H.

J Gastroenterol. 2018 Sep;53(9):1089-1097. doi: 10.1007/s00535-018-1445-3. Epub 2018 Mar 2.

PMID:
29500489
39.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.

Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.

PMID:
29427443
40.

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.

Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2017 Feb 27;1(1):46-52. doi: 10.1002/hep4.1019. eCollection 2017 Feb.

41.

[Current issues and management of long-term nucleos(t)ide analogues treatment for chronic hepatitis B].

Hosaka T, Suzuki F, Kumada H.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(1):27-35. doi: 10.11405/nisshoshi.115.27. Japanese. No abstract available.

PMID:
29353850
42.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.

Zeuzem S, Serfaty L, Vierling J, Cheng W, George J, Sperl J, Strasser S, Kumada H, Hwang P, Robertson M, Wahl J, Barr E, Talwani R, Platt H.

J Gastroenterol. 2018 May;53(5):679-688. doi: 10.1007/s00535-018-1429-3. Epub 2018 Jan 17.

PMID:
29344726
43.
44.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.

Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 May;90(5):919-925. doi: 10.1002/jmv.25023. Epub 2018 Jan 30.

PMID:
29315652
45.

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.

Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02217-17. doi: 10.1128/AAC.02217-17. Print 2018 Feb.

46.

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.

Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K.

J Gastroenterol. 2018 May;53(5):689. doi: 10.1007/s00535-017-1409-z.

47.

DEVELOPMENT OF A MULTIMODAL MONTE CARLO BASED TREATMENT PLANNING SYSTEM.

Kumada H, Takada K, Sakurai Y, Suzuki M, Takata T, Sakurai H, Matsumura A, Sakae T.

Radiat Prot Dosimetry. 2018 Aug 1;180(1-4):286-290. doi: 10.1093/rpd/ncx218.

PMID:
29087501
48.

Validation of the physical and RBE-weighted dose estimator based on PHITS coupled with a microdosimetric kinetic model for proton therapy.

Takada K, Sato T, Kumada H, Koketsu J, Takei H, Sakurai H, Sakae T.

J Radiat Res. 2018 Jan 1;59(1):91-99. doi: 10.1093/jrr/rrx057.

49.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome.

Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

BMC Gastroenterol. 2017 Oct 25;17(1):112. doi: 10.1186/s12876-017-0668-8.

50.

Performance of autotaxin as a serum marker for liver fibrosis.

Ikeda H, Kobayashi M, Kumada H, Enooku K, Koike K, Kurano M, Sato M, Nojiri T, Kobayashi T, Ohkawa R, Shimamoto S, Igarashi K, Aoki J, Yatomi Y.

Ann Clin Biochem. 2018 Jul;55(4):469-477. doi: 10.1177/0004563217741509. Epub 2017 Nov 13.

PMID:
29065699

Supplemental Content

Loading ...
Support Center